Which neurotransmitters are typically decreased with the use of antipsychotics?

The use of antipsychotic medications primarily targets the dopamine system in the brain. These medications often work by blocking dopamine receptors, particularly the D2 receptor subtype. As a result, there is a decrease in dopamine activity, which is essential for managing symptoms of psychosis, such as hallucinations and delusions. This decrease in dopamine is a fundamental mechanism by which antipsychotics exert their therapeutic effects.

In addition to dopamine, many antipsychotic medications also influence serotonin pathways. Some atypical antipsychotics, for example, not only block dopamine receptors but also have a significant impact on serotonin receptors, particularly the 5-HT2A receptors. By addressing both dopamine and serotonin, these medications can help improve a broader range of symptoms, including negative symptoms of schizophrenia.

The other neurotransmitters mentioned in the other choices do not play a central role in the mechanism of action of antipsychotics. Norepinephrine is affected to some extent, but it is not the primary target of these medications. Similarly, GABA, another inhibitory neurotransmitter, does not directly relate to the main action of antipsychotics, which focus on modulating dopaminergic and serotonergic pathways. Understanding the interaction between these neurotransmit